CN110927394A - 一种BNP、NT-proBNP、sST2的联合检测试剂条及制备方法 - Google Patents
一种BNP、NT-proBNP、sST2的联合检测试剂条及制备方法 Download PDFInfo
- Publication number
- CN110927394A CN110927394A CN201911275192.6A CN201911275192A CN110927394A CN 110927394 A CN110927394 A CN 110927394A CN 201911275192 A CN201911275192 A CN 201911275192A CN 110927394 A CN110927394 A CN 110927394A
- Authority
- CN
- China
- Prior art keywords
- antibody
- sst2
- bnp
- probnp
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 98
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 title claims abstract description 76
- 102400001263 NT-proBNP Human genes 0.000 title claims abstract description 74
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 title claims abstract description 74
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 32
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000012528 membrane Substances 0.000 claims abstract description 53
- 239000003550 marker Substances 0.000 claims abstract description 42
- 238000004458 analytical method Methods 0.000 claims abstract description 36
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims abstract description 26
- 238000010521 absorption reaction Methods 0.000 claims abstract description 18
- 238000003908 quality control method Methods 0.000 claims abstract description 12
- 239000004005 microsphere Substances 0.000 claims description 36
- 239000000243 solution Substances 0.000 claims description 25
- 239000000427 antigen Substances 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 11
- 238000005507 spraying Methods 0.000 claims description 11
- 229920002678 cellulose Polymers 0.000 claims description 9
- 239000001913 cellulose Substances 0.000 claims description 9
- 238000002372 labelling Methods 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 238000005516 engineering process Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 239000000020 Nitrocellulose Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 229920001220 nitrocellulos Polymers 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 239000004677 Nylon Substances 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000005520 cutting process Methods 0.000 claims description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims description 2
- 229920000126 latex Polymers 0.000 claims description 2
- 239000004745 nonwoven fabric Substances 0.000 claims description 2
- 239000002096 quantum dot Substances 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 210000005259 peripheral blood Anatomy 0.000 abstract description 4
- 239000011886 peripheral blood Substances 0.000 abstract description 4
- 210000002966 serum Anatomy 0.000 abstract description 4
- 206010019280 Heart failures Diseases 0.000 description 12
- 238000003317 immunochromatography Methods 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- HNGDOSBFYRVIEY-UHFFFAOYSA-N ethanesulfonic acid;hydrate Chemical compound O.CCS(O)(=O)=O HNGDOSBFYRVIEY-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 101710122194 Gene 2 protein Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 101710137426 Replication-associated protein G2P Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical group C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
本发明公开了一种BNP、NT‑proBNP、sST2的联合检测试剂条及制备方法,包括样品垫,结合垫,分析膜,吸收垫和底板;底板上依次设置有样品垫,结合垫,分析膜,吸收垫;结合垫部分搭接在分析膜的一侧;吸收垫部分搭接在分析膜的另一侧;样品垫部分搭接在结合垫上;分析膜上设置有三条检测线和一条质控线;结合垫包被有BNP抗体标记物,NT‑proBNP抗体标记物,sST2抗体标记物。本案可以联合检测,一份样本,一次加样,一次检测,同时得到BNP、NT‑proBNP、sST2三个项目的检测结果,简化操作步骤,减少样本用量,节约时间和成本;可检样本种类多,包含血清、血浆、全血和末梢血样本,且无需对样本进行前处理,操作简便,方便快捷。
Description
技术领域
本发明涉及一种检测试剂条及其制备方法。
背景技术
免疫层析技术(ImmunochromatographicAssay,ICA)是20世纪末发展起来的结合免疫技术和色谱层析技术的一种分析方法,该方法具有准确、操作简单、快速,价格便宜,稳定性好等特点,广泛应用于临床诊断、环境监测、食品安全等重要领域。
荧光免疫层析技术是基于抗原抗体特异性免疫反应的新型膜检测技术。该技术以固定有检测线(包被抗体或包被抗原)和质控线(抗抗体)的条状纤维层析材料为固定相,测试液为流动相,荧光标记抗体或抗原固定于连接垫,通过毛细管作用使待分析物在层析条上移动。对于带有多个抗原决定簇的大分子抗原(蛋白、病毒、致病菌等),通常采用“三明治”型双抗夹心免疫层析方法,即待测物在流动相作用下先与荧光标记抗体结合,当到达检测线时再与包被抗体结合形成双抗夹心的“三明治”型。对于只具有单一抗原表位的小分子抗原(农兽药、违禁药物等),待测小分子抗原与荧光标记抗体结合后,由于空间位阻作用难以再与检测线上的包被抗体结合。所以,具有单一抗原表位的小分子待测物多采用竞争免疫层析法检测。
心血管疾病是中国城市人口和西方发达国家的主要疾病和主要死亡原因之一,其中心力衰竭 (heart failure, HF) 更严重危害着人类的生命健康。对HF患者进行迅速有效的诊断和及时治疗和预后评估有十分重要的意义。心力衰竭的生物标志物( 以下可简称为“心衰标志物”) 不仅能够准确诊断心力衰竭,评价其严重程度,还能指导临床治疗和疗效的监测,判断心力衰竭的预后。临床上,HF的标准物如N端脑钠肽前体(NT-proBNP)和B型钠尿肽(BNP)已广泛应用,仍然具有一段局限性,可溶性生长刺激表达基因2蛋白(sST2)作为一种新型心衰标志物,不受年龄、体质量指数、心房颤动、心力衰竭原发病病因(如缺血与非缺血)等的影响。因此各种不同类型的心衰标志物的联合并行检测已成为必然,而多指标并行检测的高通量迅速性、准确性和稳定性就更加至关重要。
发明内容
本发明目的是:提供了一种一次可以同时测得BNP、NT-proBNP、sST2三个项目的检测结果试剂条及制备方法,联合检测样本用量少,节约时间,降低成本,可检测的样本种类多,适用广泛。
本发明的技术方案是:一种BNP、NT-proBNP、sST2的联合检测试剂条,包括样品垫,结合垫,分析膜,吸收垫和底板;所述底板上依次设置有样品垫,结合垫,分析膜,吸收垫;所述结合垫部分搭接在分析膜的一侧;所述吸收垫部分搭接在分析膜的另一侧;所述样品垫部分搭接在结合垫上;所述分析膜上设置有三条检测线和一条质控线;三条检测线分别是BNP检测线、NT-proBNP检测线、sST2检测线;结合垫包被有BNP抗体标记物,NT-proBNP抗体标记物,sST2抗体标记物。
优选的,所述BNP检测线包被有BNP检测抗体、所述NT-proBNP检测线包被有NT-proBNP检测抗体、所述sST2检测线包被有sST2检测抗体。
优选的,所述BNP检测抗体和BNP抗体标记物的BNP抗体具有不同的抗原结合位点;所述NT-proBNP检测抗体和NT-proBNP抗体标记物的NT-proBNP抗体具有不同的抗原结合位点;所述sST2检测抗体和sST2抗体标记物的sST2抗体具有不同的抗原结合位点。
优选的,所述标记物为易测定又具有高度敏感性的物质。
优选的,所述标记物为荧光素、磷光素、荧光微球、磷光微球、胶体金、酶、生物素、磁性微球、发光底物、彩色胶乳、量子点中的一种或多种。
优选的,所述样品垫和结合垫采用玻璃纤维素膜或聚酯纤维素膜或纤维素滤纸或无纺布。
优选的,所述分析膜材采用硝酸纤维素膜或者尼龙膜。
本案的试剂条可用于血清、血浆、全血及末梢血的样本中BNP/NT-proBNP/sST2定量(定性)检测。将样本加入加样口,加入一定体积0~200 μL样本稀释液(如0.09% NaCl),3-30 min后通过配套仪器进行检测并自动计算,即可得到样本中BNP/NT-proBNP/sST2的浓度。
一种BNP、NT-proBNP、sST2的联合检测试剂条的制备方法:具体制备步骤包括:
1)抗体标记:利用抗体标记技术,分别将BNP、NT-proBNP、sST2抗体与标记物标记,形成抗体标记物复合物溶液或混悬液,抗体浓度为0.05 mg/mL ~ 5mg/L;
抗体标记技术采用抗体标记荧光微球:微球活化:向0.1~10 mg/ml荧光微球中加入用10~100 mM,pH 5.0~9.0 MES(2-(N-吗啉)乙磺酸一水合物 )溶解的0.1~10 mg EDC(1-(3-二甲氨基丙基)-3-乙基碳二亚胺)和0.1~10 mg NHS(N-羟基琥珀酰亚胺),活化10~600 min,7000~15000 rpm离心5~30 min,弃上清,沉淀用pH 5.0~9.0的10~100 mM PBS重悬,得到0.1~10 mg/ml活化的荧光微球溶液;抗体偶联:将0.1~10.0 mg BNP、NT-proBNP、sST2标记抗体分别加入0.1~10 mg/ml活化的荧光微球溶液中,室温混匀0.5~24h,7000~15000 rpm离心5~30 min,弃上清,沉淀用含0.5~50mg BSA(牛血清白蛋白)的10~100 mM PBS(磷酸盐缓冲液)溶液封闭0.5~24 h,搅拌混匀,7000~15000 rpm离心5~30min,收集的沉淀保存于pH 6.0~8.0、0~100 mM Tris缓冲液中,得到BNP抗体标记荧光微球溶液、NT-proBNP抗体标记荧光微球溶液、sST2抗体标记荧光微球溶液;
2)结合垫制作:将步骤1)中得到的BNP抗体标记物、NT-proBNP抗体标记物、sST2抗体标记物按照体积比混合成抗体标记物混合液,BNP抗体标记物溶液的体积为0.5%~90%,NT-proBNP抗体标记物溶液的体积为0.5%~90%,sST2抗体标记物溶液的体积为0.5%~90%;按照0.25~15 μL/cm喷涂在结合膜材上,即为结合垫,干燥备用;
3)分析膜制作:分别将BNP检测抗体、NT-proBNP检测抗体、sST2检测抗体和质控线稀释至0.1~5 mg/ml,在点膜仪上以0.25~4.0μL/cm的喷量喷涂在分析膜材上,形成BNP检测线、NT-proBNP检测线、sST2检测线和质控线,即为分析膜,干燥备用;
4)试剂条的组装:将样品垫、结合垫、分析膜和吸收垫依次搭接地粘贴在底板上且分别部分重合,即得BNP、NT-proBNP、sST2联合检测试剂条;BNP、NT-proBNP、sST2联合检测试剂条可装入卡壳,也可不装卡壳直接使用。
优选的,将黏贴有样品垫、结合垫、分析膜和吸收垫的底板裁切成长度为5~10cm,宽度为2~8 mm的条形。
优选的,所述底板为PVC底板。
本发明的优点是:
1、联合检测,一份样本,一次加样,一次检测,同时得到BNP、NT-proBNP、sST2三个项目的检测结果,简化操作步骤,减少样本用量,节约时间,节省成本;
2、可检样本种类多,包含血清、血浆、全血和末梢血的样本,且无需对样本进行前处理,操作简便,方便快捷;
3、试剂条可装入任意形式外卡壳,也可不装外卡壳直接使用,实用性强,灵活方便。
附图说明
下面结合附图及实施例对本发明作进一步描述:
图1本案所述的一种BNP、NT-proBNP、sST2的联合检测试剂条的结构示意图;
图2为本案一种BNP、NT-proBNP、sST2的联合检测试剂条在临床进行测试,绘制BNP、NT-proBNP、sST2的ROC曲线
其中:1、样品垫;2、结合垫;3、分析膜;4、吸收垫;5、底板;31、检测线;32、质控线。
具体实施方式
实施例:
如附图1-2所示,一种BNP、NT-proBNP、sST2的联合检测试剂条,其特征在于:包括样品垫1,结合垫2,分析膜3,吸收垫4和底板5;所述底板6上依次设置有品垫1,结合垫2,分析膜3,吸收垫4;所述结合垫3部分搭接在分析膜3的一侧;所述吸收垫4部分搭接在分析膜3的另一侧;所述样品垫1部分搭接在结合垫2上;所述分析膜上设置有三条检测线31和一条质控线32;三条检测线分别是BNP检测线、NT-proBNP检测线、sST2检测线;结合垫包被有BNP抗体标记物,NT-proBNP抗体标记物,sST2抗体标记物。
所述BNP检测线包被有BNP检测抗体、所述NT-proBNP检测线包被有NT-proBNP检测抗体、所述sST2检测线包被有sST2检测抗体;所述BNP检测抗体和BNP抗体标记的荧光微球的BNP抗体具有不同的抗原结合位点;所述NT-proBNP检测抗体和NT-proBNP抗体标记的荧光微球的NT-proBNP抗体具有不同的抗原结合位点;所述sST2检测抗体和sST2抗体标记的荧光微球的sST2抗体具有不同的抗原结合位点;所述标记物为易测定又具有高度敏感性的物质;结合垫同时包被三种标记过的荧光微球,分别为BNP抗体标记荧光微球、NT-proBNP抗体标记荧光微球、sST2抗体标记荧光微球,可分别与对应检测线上的抗体和待测物形成双抗体夹心。
本例中所述标记物为荧光微球;所述样品垫和结合垫采用玻璃纤维素膜;所述分析膜材采用硝酸纤维素膜。
一种BNP、NT-proBNP、sST2的联合检测试剂条的制备方法:具体制备步骤包括:
1)抗体标记:抗体标记荧光微球:微球活化:向1 mg/ml荧光微球中加入用50 mM,pH7.0 MES(2-(N-吗啉)乙磺酸一水合物 )溶解的5 mg EDC(1-(3-二甲氨基丙基)-3-乙基碳二亚胺)和5mg NHS(N-羟基琥珀酰亚胺),活化60 min, 15000 rpm离心30 min,弃上清,沉淀用pH 7.0的50 mM PBS(磷酸盐缓冲液)重悬,得到1 mg/ml活化的荧光微球溶液;抗体偶联:将1.0 mg BNP、NT-proBNP、sST2标记抗体分别加入1 mg/ml活化的荧光微球溶液2 ml中,室温混匀1 h, 15000 rpm离心30 min,弃上清,沉淀用含5 mg BSA(乙酰胺)的50 mMPBS(磷酸盐缓冲液)溶液封闭1 h,搅拌混匀, 15000 rpm离心30 min,收集的沉淀保存于pH7.0含0.5 % BSA(牛血清白蛋白)的20 mM Tris缓冲液中,得到浓度为0.1mg/ml BNP抗体标记荧光微球溶液、0.1mg/ml NT-proBNP抗体标记荧光微球溶液、0.1mg/ml sST2抗体标记荧光微球溶液;
2)结合垫制作:将步骤1)中得到的BNP抗体标记荧光微球溶液、NT-proBNP抗体标记荧光微球溶液、sST2抗体标记荧光微球溶液按照一定体积比1:1:1混合成荧光微球混合液,按照10 μL/cm喷涂在结合膜材上,即为结合垫干燥备用;
3)分析膜制作:分别将BNP检测抗体、NT-proBNP检测抗体、sST2检测抗体和质控线稀释至1mg/ml,在点膜仪上以1μL/cm的喷量喷涂在硝酸纤维素膜上,形成BNP检测线、NT-proBNP检测线、sST2检测线和质控线,即为分析膜,干燥备用;
4)试剂条的组装:将样品垫、结合垫、分析膜和吸收垫依次搭接地粘贴在PVC底板上且分别部分重合,将黏贴有样品垫、结合垫、分析膜和吸收垫的PVC底板裁切成长度为7.5cm,宽度为4 mm的纸条,并装入卡壳以及包装中,即得BNP、NT-proBNP、sST2联合检测试剂条;试剂条可装入任意形式外卡壳,也可不装外卡壳直接使用。
本案的试剂条可用于血清、血浆、全血及末梢血的样本中BNP/NT-proBNP/sST2定量(定性)检测,且无需对样本进行前处理,操作简便,方便快捷。将样本加入加样口,加入一定体积0~200 μL样本稀释液(如0.09% NaCl),3-30 min后通过配套仪器进行检测并自动计算,即可得到样本中BNP/NT-proBNP/sST2的浓度。一份样本,一次加样,一次检测,同时得到BNP、NT-proBNP、sST2三个项目的检测结果,简化操作步骤,减少样本用量,节约时间,节省成本。
应用本案所述的试剂条在临床进行测试,绘制BNP、NT-proBNP、sST2的ROC曲线。如表1和图2所示。由表1和图2可知,联合检测的ROC曲线下面积更大,联合检测对心衰的诊断有更高的正确率。表1如下:
变量 | AUC | SE <sup>a</sup> | 95% CI <sup>b</sup> |
联合检测 | 0.928 | 0.0315 | 0.840 - 0.976 |
NT-proBNP | 0.902 | 0.0351 | 0.807 - 0.961 |
BNP | 0.897 | 0.0361 | 0.801 - 0.957 |
sST2 | 0.914 | 0.0315 | 0.822 - 0.96 |
本案中的荧光微球可以用任意发光物质,磁性物质代替;分析膜可以是硝酸纤维素膜或者尼龙膜或者体他替代膜材;样品垫和结合垫为玻璃纤维素膜或聚酯纤维素膜或其他替代膜材;底板可为PVC或其他替代板材;加样方式可以是直接加样,可以稀释后加样,可以是加样后再加入稀释液。
上述实施例仅例示性说明本发明的原理及其功效,而非用于限制本发明的。任何熟悉此技术的人士皆可在不违背本发明的精神及范畴下,对上述实施例进行修饰或改变。因此,举凡所属技术领域中具有通常知识者在未脱离本发明的所揭示的精神与技术思想下所完成的一切等效修饰或改变,仍应由本发明的权利要求所涵盖。
Claims (9)
1.一种BNP、NT-proBNP、sST2的联合检测试剂条,其特征在于:包括样品垫,结合垫,分析膜,吸收垫和底板;所述底板上依次设置有样品垫,结合垫,分析膜,吸收垫;所述结合垫部分搭接在分析膜的一侧;所述吸收垫部分搭接在分析膜的另一侧;所述样品垫部分搭接在结合垫上;所述分析膜上设置有三条检测线和一条质控线;三条检测线分别是BNP检测线、NT-proBNP检测线、sST2检测线;结合垫包被有BNP抗体标记物,NT-proBNP抗体标记物,sST2抗体标记物。
2.根据权利要求1所述的一种BNP、NT-proBNP、sST2的联合检测试剂条,其特征在于:所述BNP检测线包被有BNP检测抗体、所述NT-proBNP检测线包被有NT-proBNP检测抗体、所述sST2检测线包被有sST2检测抗体。
3.根据权利要求2所述的一种BNP、NT-proBNP、sST2的联合检测试剂条,其特征在于:所述BNP检测抗体和BNP抗体标记物的BNP抗体具有不同的抗原结合位点;所述NT-proBNP检测抗体和NT-proBNP抗体标记物的NT-proBNP抗体具有不同的抗原结合位点;所述sST2检测抗体和sST2抗体标记物的sST2抗体具有不同的抗原结合位点。
4.根据权利要求1所述的一种BNP、NT-proBNP、sST2的联合检测试剂条,其特征在于:所述标记物为易测定又具有高度敏感性的物质。
5.根据权利要求4所述的一种BNP、NT-proBNP、sST2的联合检测试剂条,其特征在于:所述标记物为荧光素、磷光素、荧光微球、磷光微球、胶体金、酶、生物素、磁性微球、发光底物、彩色胶乳、量子点中的一种或多种。
6.根据权利要求1所述的一种BNP、NT-proBNP、sST2的联合检测试剂条,其特征在于:所述样品垫和结合垫采用玻璃纤维素膜或聚酯纤维素膜或纤维素滤纸或无纺布。
7.根据权利要求1所述的一种BNP、NT-proBNP、sST2的联合检测试剂条,其特征在于:所述分析膜材采用硝酸纤维素膜或者尼龙膜。
8.一种BNP、NT-proBNP、sST2的联合检测试剂条的制备方法:其特征在于:具体制备步骤包括:
1)抗体标记:利用抗体标记技术,分别将BNP、NT-proBNP、sST2抗体与标记物标记,形成抗体标记物复合物溶液或混悬液,抗体浓度为0.05 mg/mL ~ 5mg/L;
2)结合垫制作:将步骤1)中得到的BNP抗体标记、NT-proBNP抗体标记、sST2抗体标记按照体积比混合成抗体标记物混合液,BNP抗体标记物溶液的体积为0.5%~90%,NT-proBNP抗体标记物溶液的体积为0.5%~90%,sST2抗体标记物溶液的体积为0.5%~90%;按照0.25~15 μL/cm喷涂在结合膜材上,即为结合垫,干燥备用;
3)分析膜制作:分别将BNP检测抗体、NT-proBNP检测抗体、sST2检测抗体和质控线稀释至0.1~5 mg/ml,在点膜仪上以0.25~4.0μL/cm的喷量喷涂在分析膜材上,形成BNP检测线、NT-proBNP检测线、sST2检测线和质控线,即为分析膜,干燥备用;
4)试剂盒的组装:将样品垫、结合垫、分析膜和吸收垫依次搭接地粘贴在底板上且分别部分重合,即得BNP、NT-proBNP、sST2联合检测试剂条。
9.根据权利要求8所述的一种BNP、NT-proBNP、sST2的联合检测试剂条的制备方法,其特征在于:将黏贴有样品垫、结合垫、分析膜和吸收垫的底板裁切成长度为5~10 cm,宽度为2~8 mm的条形。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911275192.6A CN110927394A (zh) | 2019-12-12 | 2019-12-12 | 一种BNP、NT-proBNP、sST2的联合检测试剂条及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911275192.6A CN110927394A (zh) | 2019-12-12 | 2019-12-12 | 一种BNP、NT-proBNP、sST2的联合检测试剂条及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110927394A true CN110927394A (zh) | 2020-03-27 |
Family
ID=69859133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911275192.6A Pending CN110927394A (zh) | 2019-12-12 | 2019-12-12 | 一种BNP、NT-proBNP、sST2的联合检测试剂条及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110927394A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112067824A (zh) * | 2020-08-13 | 2020-12-11 | 河南沃迈生物科技有限公司 | 一种bnp检测试剂盒 |
CN112285364A (zh) * | 2020-11-05 | 2021-01-29 | 南京申基医药科技有限公司 | 一种联合检测风湿三项的试剂盒及其制备方法 |
CN113311173A (zh) * | 2021-07-28 | 2021-08-27 | 南京申基医药科技有限公司 | 一种检测血液样本中ST2和Galectin-3抗体的联检试纸条、制备方法和试剂盒 |
WO2022101937A1 (en) * | 2020-11-12 | 2022-05-19 | Shah Komal | An integrated health data capture and analysis based device for evaluation, diagnosis and prognosis of heart failure |
WO2023129991A1 (en) * | 2021-12-30 | 2023-07-06 | Analog Devices Inc. | Devices and methods for the detection of probnp |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104865387A (zh) * | 2015-05-20 | 2015-08-26 | 瑞莱生物科技(江苏)有限公司 | 快速定量检测ST2和NT-proBNP的免疫荧光试纸条及其制备方法 |
CN105785028A (zh) * | 2012-08-10 | 2016-07-20 | 杭州华得森生物技术有限公司 | 一种检测人心力衰竭新型标志物st2的快速诊断试剂盒 |
CN107328926A (zh) * | 2017-06-29 | 2017-11-07 | 海格德生物科技(深圳)有限公司 | 快速检测多项心衰标志物的试剂卡、制备方法及检测方法 |
CN208833778U (zh) * | 2018-12-13 | 2019-05-07 | 迪亚莱博(张家港)生物科技有限公司 | 一种检测NT-proBNP和ST2的试纸条及试剂盒 |
-
2019
- 2019-12-12 CN CN201911275192.6A patent/CN110927394A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105785028A (zh) * | 2012-08-10 | 2016-07-20 | 杭州华得森生物技术有限公司 | 一种检测人心力衰竭新型标志物st2的快速诊断试剂盒 |
CN104865387A (zh) * | 2015-05-20 | 2015-08-26 | 瑞莱生物科技(江苏)有限公司 | 快速定量检测ST2和NT-proBNP的免疫荧光试纸条及其制备方法 |
CN107328926A (zh) * | 2017-06-29 | 2017-11-07 | 海格德生物科技(深圳)有限公司 | 快速检测多项心衰标志物的试剂卡、制备方法及检测方法 |
CN208833778U (zh) * | 2018-12-13 | 2019-05-07 | 迪亚莱博(张家港)生物科技有限公司 | 一种检测NT-proBNP和ST2的试纸条及试剂盒 |
Non-Patent Citations (2)
Title |
---|
张国梁等: "sST2、BNP、NT-proBNP对HF患者鉴别诊断意义", 《世界最新医学信息文摘》 * |
杨阳等: "心力衰竭患者B型利钠肽、B型氨基端利钠肽原和可溶性ST2水平变化及意义", 《广东医学》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112067824A (zh) * | 2020-08-13 | 2020-12-11 | 河南沃迈生物科技有限公司 | 一种bnp检测试剂盒 |
CN112285364A (zh) * | 2020-11-05 | 2021-01-29 | 南京申基医药科技有限公司 | 一种联合检测风湿三项的试剂盒及其制备方法 |
WO2022101937A1 (en) * | 2020-11-12 | 2022-05-19 | Shah Komal | An integrated health data capture and analysis based device for evaluation, diagnosis and prognosis of heart failure |
CN113311173A (zh) * | 2021-07-28 | 2021-08-27 | 南京申基医药科技有限公司 | 一种检测血液样本中ST2和Galectin-3抗体的联检试纸条、制备方法和试剂盒 |
WO2023129991A1 (en) * | 2021-12-30 | 2023-07-06 | Analog Devices Inc. | Devices and methods for the detection of probnp |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110927394A (zh) | 一种BNP、NT-proBNP、sST2的联合检测试剂条及制备方法 | |
US11959912B2 (en) | Fluorescence immunochromatographic detection card and a preparation method therefor and use thereof | |
CN211235888U (zh) | 一种免疫检测试剂盒 | |
CN108254550B (zh) | 检测ck-mb的时间分辨荧光免疫层析试纸条、试剂盒及其制备方法 | |
CN109239361B (zh) | 一种心肌肌钙蛋白i的检测试剂盒及其制备方法 | |
EP3904878B1 (en) | Immunochromatography strip for pregnancy diagnosis with multiple test lines, and pregnancy diagnosis kit comprising same | |
CN108398562A (zh) | 胱抑素c荧光微球免疫层析定量检测试纸条及试纸卡 | |
CN106248958A (zh) | 一种定量检测cTnI的荧光免疫层析试剂及制备方法 | |
CN102323422A (zh) | 半定量同时检测cTnI和Myo的免疫层析试纸条及其制备 | |
CN106153927A (zh) | 一种快速定量同时检测cTnI、CKMB、Myo的时间分辨荧光免疫层析试剂及制备方法 | |
CN107219371A (zh) | Pct荧光微球免疫层析检测试剂卡及其制备方法 | |
CN107907679A (zh) | 一种免疫层析试纸条及其制作方法与应用 | |
CN102207507A (zh) | 心肌肌钙蛋白半定量检测试纸及制备方法 | |
CN107918022B (zh) | 一种cTnI检测试剂盒及其使用方法 | |
CN109239335A (zh) | 联检试纸条及其制备方法 | |
CN110873800A (zh) | 糖化血红蛋白免疫层析试纸条及其制备方法和试剂盒 | |
CN111983243A (zh) | 氨基末端脑利钠肽前体测定试剂盒、制备方法及检测方法 | |
CN114441766B (zh) | 一种定量检测抗pla2r抗体的荧光免疫层析试纸条及其制备方法 | |
CN115436627A (zh) | 一种胱抑素c荧光免疫层析检测试剂盒及其制备方法 | |
CN205484371U (zh) | 一种肿瘤标志物检测试剂盒 | |
CN107782898B (zh) | 一种荧光免疫层析法检测试剂盒及其检测方法 | |
CN108918865A (zh) | 荧光免疫层析试纸条及试剂卡 | |
CN110873801A (zh) | 甲状腺激素免疫层析试纸条及其制备方法和试剂盒 | |
CN116047062A (zh) | 一种多联检量子点定量检测卡及其制备方法 | |
CN116413444A (zh) | 一种检测总三碘甲状腺原氨酸含量的试剂盒及其检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200327 |
|
RJ01 | Rejection of invention patent application after publication |